1-3 of 3
Ravinder Dhawan, PhD
Close
Sort by
Journal Articles

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

Si-Tien Wang, MS, Hui Huang, PhD, MBA, Abbie Ba-Mancini, BS, MBA, Hongliang Shi, MS, Kristina Chen, MS, Caroline Korves, ScD, Ravinder Dhawan, PhD, Andrew Cakana, FRCPath, MD, Helgi van de Velde, Dixie-Lee W. Esseltine, MD, FRCPC, Mei S. Duh, ScD, MPH
Journal: Blood
Blood (2010) 116 (21): 2563.
https://doi.org/10.1182/blood.V116.21.2563.2563
Published: 2010
Journal Articles

Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory Multiple Myeloma: An Interim Report from an International Electronic Observational Study

Meletios A. Dimopoulos, Hadewijch M De Samblanx, MD, Maria G Roussou, Konstantinos Zervas, Eirini Katodritou, Deniz Sargin, MD, Cyrille Hulin, MD, Lucia Ahlberg, MD, Javier De La Rubia, Rita Ganguly, PhD, Joris K Diels, MSc, Helgi van de Velde, MD, PhD, Ravinder Dhawan, PhD, Michael D Spencer, MSc, Michel Delforge, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3027.
https://doi.org/10.1182/blood.V116.21.3027.3027
Published: 2010
Journal Articles

Response to Bortezomib Therapy for Multiple Myeloma (MM) in Actual Clinical Practice: Preliminary Effectiveness Findings of an International Observational Study.

Michel Delforge, MD, PhD, Eirini Katodritou, MD, PhD, Konstantinos Zervas, MD, PhD, Deniz Sargin, MD, Cyrille Hulin, MD, Mats Linderholm, MD, PhD, Evgenia Verrou, MD, Vicki Poon, MPH, Ravinder Dhawan, PhD
Journal: Blood
Blood (2007) 110 (11): 4837.
https://doi.org/10.1182/blood.V110.11.4837.4837
Published: 2007